去势小鼠尾静脉注射骨髓间充干细胞通过抑制体内破骨细胞活性治疗绝经后骨质疏松

Mesenchymal stem cell infusion ameliorates osteoporotic phenotype in ovariectomized mice by inhibiting osteoclast survival

目的探讨骨髓间充质干细胞(BMMSCs)尾静脉注射对体内破骨细胞活性及骨质疏松治疗作用。方法选用8周龄健康雌性小鼠行双侧卵巢切除术(OVX),建立绝经后骨质疏松模型。选用同一批次、周龄相同、体质量相近的健康小鼠行双侧卵巢附近脂肪组织部分切除,建立假手术组(sham)。对OVX组小鼠尾静脉注射BMMSC治疗,1个月后分别取双侧股骨行TRAP染色及mciro-CT检测体内破骨细胞数量和骨小梁微结构改变。结果 OVX+BMMSC注射组中破骨细胞的数量较OVX不治疗组显著降低。micro-CT显示OVX+BMMSC组骨小梁数量及骨密度显著高于OVX不治疗组。结论尾静脉注射骨髓间充质干细胞能够抑制体内破骨细胞活性,对绝经后骨质疏松具有一定的治疗作用。

This study aimed to investigate the osteoelast survival changes and therapeutic effects exerted by caudal veins injection of bone marrow-derived mesenchymal stem cells （BMMSC） in mice during postmenopausal osteoporosis （OP）. An animal model of OP was established by ovariectomy （OVX, bilateral ovarian resection） in 8- week-old healthy female mice. Then BMMSC were injected via caudal veins in treatment group. One mouth later, TRAP staining and miero-CT scanning were conducted to detect osteoelast survival and bone mierostructure in femoral cancellous bone. Compare with the untreated group, osteoclast activity in treated group was significant declined （P〈 0.05）, while the trabecular volume （BV/TV）, bone mineral density （BMD） and trabecular number （Tb.N/ ram） were significant enhanced （P 〈 0.05）. These results indicated that BMMSC play a critical role in treating postmenopausal osteoporosis by inhibiting activity of osteoelast.